Common CTD Dossier Gaps Before a Pharmaceutical Submission in Chile

CTD structure does not guarantee product consistency

The CTD creates a common documentary architecture, but every Chile submission still concerns one defined pharmaceutical product. Problems frequently arise when modules were assembled at different times, for different markets or before a manufacturing change was fully propagated.

A useful review therefore compares information across modules instead of checking files only against a list.

Five recurring gap areas

The exact evidence depends on the product and route, but several categories repeatedly require coordination before a submission can be controlled.

• Product identity: inconsistent names, strengths, dosage forms, compositions or presentations.
• Manufacturing chain: unclear responsibilities, site addresses, legal names or manufacturing steps.
• Analytical package: specifications, methods, validation and certificates that do not align.
• Stability: unsupported shelf life, storage condition, packaging configuration or batch representativeness.
• Local documents: labels, leaflets, certificates, powers and declarations that describe a different product baseline.

Translate gaps into accountable requests

A gap list is valuable only if each item identifies the document or decision needed, the responsible source, the dependency it affects and the point at which the project cannot continue without resolution.

For portfolios, a common baseline can reduce repeated requests, but product-specific evidence should never be assumed simply because another dossier from the same company contains it.

High-risk or unusual products need a different first question

An unusual active substance, dosage form or proposed pathway may require a specific feasibility assessment before a normal registration scope is defined. This is an exception, not a diagnostic stage that every ordinary dossier should be forced to purchase.

The aim is to distinguish a correctable documentary gap from a fundamental regulatory feasibility issue.